Microfluidic hemophilia models using blood from healthy donors
Abstract Background Microfluidic clotting assays permit drug action studies for hemophilia therapeutics under flow. However, limited availability of patient samples and Inter‐donor variability limit the application of such assays, especially with many patients on prophylaxis. Objective To develop ap...
Enregistré dans:
Auteurs principaux: | Xinren Yu, Karen A. Panckeri, Lacramioara Ivanciu, Rodney M. Camire, Carmen H. Coxon, Adam Cuker, Scott L. Diamond |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/71da544d77aa43e085358a8ca40dc390 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
par: Haowei (Linda) Sun, et autres
Publié: (2021) -
Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
par: Jennifer Stimec, et autres
Publié: (2021) -
COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A
par: Can Alp GENÇ, et autres
Publié: (2021) -
Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
par: Samuel sarmiento Doncel, et autres
Publié: (2021) -
External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data
par: Pierre Chelle, et autres
Publié: (2021)